Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
51.78 USD | -2.05% |
|
-0.62% | -38.32% |
06-24 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
06-17 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.32% | 6.14B | |
+16.40% | 122B | |
+21.30% | 116B | |
+22.47% | 27.03B | |
-21.20% | 20.36B | |
-17.03% | 16.43B | |
-17.85% | 15.91B | |
-44.35% | 15.6B | |
+57.43% | 14.94B | |
+1.05% | 13.59B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- Cytokinetics Insider Sold Shares Worth $425,700, According to a Recent SEC Filing